Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter StudySiamak Daneshmand, Jeffrey A. Jones, Michael A. O’Donnell et al.|The Journal of Urology|2017Cited by 109
Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018Yair Lotan, Siamak Daneshmand, Trinity J. Bivalacqua et al.|Nature Reviews Urology|2019Cited by 84
Patient‐reported outcomes of blue‐light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre studyAngela B. Smith, Siamak Daneshmand, Sanjay Patel et al.|British Journal of Urology|2018Cited by 21
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center studyKamal S. Pohar, Siamak Daneshmand, Sanjay Patel et al.|Urologic Oncology Seminars and Original Investigations|2022Cited by 8
PPTLBA-02 BLUE LIGHT FLEXIBLE CYSTOSCOPY (BLFC) WITH HEXAMINOLEVULINATE (HAL) AND WHITE LIGHT FLEXIBLE CYSTOSCOPY: A PROSPECTIVE, COMPARATIVE, WITHIN-PATIENT CONTROLLED MULTI-CENTER PHASE 3 STUDY IN THE DETECTION OF BLADDER CANCER DURING SURVEILLANCESiamak Daneshmand, Stephen Jones, Sanjay Patel et al.|The Journal of Urology|2017Cited by 2